1. Home
  2. LITE vs REGN Comparison

LITE vs REGN Comparison

Compare LITE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lumentum Holdings Inc.

LITE

Lumentum Holdings Inc.

HOLD

Current Price

$925.60

Market Cap

61.1B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$796.95

Market Cap

68.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LITE
REGN
Founded
2015
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1B
68.8B
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
LITE
REGN
Price
$925.60
$796.95
Analyst Decision
Buy
Buy
Analyst Count
15
25
Target Price
$645.43
$830.16
AVG Volume (30 Days)
4.6M
766.3K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
0.55%
EPS Growth
104.56
8.19
EPS
2.59
18.95
Revenue
$1,247,700,000.00
$5,872,227,000.00
Revenue This Year
$79.88
$12.45
Revenue Next Year
$66.61
$10.13
P/E Ratio
$361.39
$42.11
Revenue Growth
24.57
20.82
52 Week Low
$111.20
$541.00
52 Week High
$1,085.68
$821.11

Technical Indicators

Market Signals
Indicator
LITE
REGN
Relative Strength Index (RSI) 60.65 77.83
Support Level $810.55 $738.17
Resistance Level $945.25 $818.06
Average True Range (ATR) 78.19 21.79
MACD 20.75 7.78
Stochastic Oscillator 91.76 91.45

Price Performance

Historical Comparison
LITE
REGN

About LITE Lumentum Holdings Inc.

Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: